Fig. 1

The expression level of ACBD3 in normal tissues and different TCGA tumors. (*p < 0.05, **p < 0.01, ***p < 0.001). adrenocortical cancer (ACC), bladder cancer (BLCA), breast cancer (BRCA), cervical cancer (CESC), bile duct cancer (CHOL), colon cancer (COAD), large B-cell lymphoma (DLBC), esophageal cancer (ESCA), Glioblastoma (GBM), head and neck cancer (HNSC), kidney chromophobe (KICH), kidney clear cell carcinoma (KIRC), kidney papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian cancer (OV), pancreatic cancer (PAAD), pheochromocytoma & paraganglioma (PCPG), prostate cancer (PRAD), rectal cancer (READ), sarcoma (SARC), melanoma (SKCM), stomach cancer (STAD), testicular cancer (TGCT), thyroid cancer (THCA), thymoma (THYM), endometrioid cancer (UCEC), uterine carcinosarcoma (UCS), ocular melanomas (UVM). A ACBD3 expression was statistically upregulated in eleven cancer types as compared to normal tissues, including BRCA, CHOL, COAD, ESCA, GBM, HNSC, KIRC, LIHC, LUAD, LUSC, STAD, and downregulated in KICH, THCA, and UCEC; B In comparison with the adjacent normal tissues, ACBD3 expression was statistically upregulated in thirteen cancers, including STAD, PRAD, PAAD, LUSC, LUAD, LIHC, KIRP, KIRC, HNSC, ESCA, CHOL, BRCA, and BLCA, and downregulated in KICH and THCA; C The expression level of ACBD3 in various pathological stages of BLCA, KIRC, and OV. ACBD3 expressed the highest in stage III of BLCA, stage I of KIRC, and stage II of OV